Number of lymph node in early-stage cervical cancer after radical surgery, does it matter?

Pedrada Innao¹, Nontawat Benjakul², Woraphot Chaowawanit¹, ²

¹Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, 10300 Bangkok, Thailand
²Department of Anatomical Pathology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, 10300 Bangkok, Thailand

*Correspondence: woraphot@nmu.ac.th (Woraphot Chaowawanit)

Submitted: 25 June 2021 Revised: 27 July 2021 Accepted: 11 August 2021 Published: 15 December 2021

Objective: To determine the number of lymph nodes obtained from radical hysterectomy with pelvic lymphadenectomy (RHPL) and survival rates of the early-stage cervical cancer patients with various numbers of removed lymph nodes (RLNs) and metastatic lymph nodes (MLNs). Materials and methods: 407 patients with early-stage cervical cancers who underwent RHPL were included in this study. We reviewed all medical records from January 2005–June 2020 and excluded the patients who had incomplete medical record, loss of follow-up visits and received neo-adjuvant chemotherapy. Results: Three-hundred-and-fifty-four patients were analyzed. The median time of follow-up was 44.3 months, the average number of RLNs was 23 (range 7–29) and 91.7% of our cases had >12 RLNs. MLNs were found in 36 cases (10.2%). The patients with RLNs <12 had a significantly lower 5-year cancer-specific survival (CSS) compared to those with RLNs >12 (73.6% and 97.0%, respectively, p-value < 0.001) but 5-year progression-free survival (PFS) was not different between both groups. Based on lymph node status, the 5-year PFS and CSS of node-negative vs. node-positive patients were 99.3% vs. 76.2% and 97.5% vs. 74.0%, respectively. Conclusion: An extensive lymphadenectomy had a survival benefit in early-stage cervical cancer patients. The patients with RLNs >12 had better 5-year CSS. MLNs and RLNs <12 are significant prognostic factors for PFS and CSS.

Keywords
Early-stage cervical cancer; Lymphadenectomy; Number of lymph node; Survival outcome

1. Introduction

Cervical cancer is the fourth most common cancer worldwide. In 2018, there were 569,847 new cases and 311,365 deaths [1]. The majority of new cases and deaths occur in developing countries. In Thailand, cervical cancer is the second most common cancer with 14.2% of incidences [2]. There were approximately 9158 new cases and 4705 deaths in 2020.

The standard treatment of early-stage cervical cancer is radical hysterectomy with pelvic lymphadenectomy (RHPL) [3]. The adjuvant treatments are considered for the patient with some post-operative factors including lymph node status, surgical margin, lymph vascular space invasion (LVSI), stromal invasion and tumor size [3–6]. Many studies reported that lymph node metastasis is an important prognostic factor affecting survival outcomes [5, 7].

The therapeutic role of more extensive lymphadenectomy in cervical cancer is controversial. The analysis of the Surveillance, Epidemiology, and End Results (SEER) database reported that a more extensive lymphadenectomy is associated with improved survival in the early-stage cervical cancer patients with negative lymph node [8]. On the other hand, Mao et al. [9] showed that the number of removed lymph nodes (RLNs) is not an independent prognostic factor for patients with node-negative early cervical cancer.

Although the European Organization for Research and Treatment of Cancer—Gynecological Cancer Group (EORTC-GCG) purposed that pelvic lymphadenectomy specimens containing more than 11 examined lymph nodes is one of the quality indicators for RHPL [10], there is no consensus in a minimum number of RLNs related to the prognosis. This study was conducted to determine the number of lymph nodes obtained from RHPL and survival rates of the early-stage cervical cancer patients with various number of RLNs and metastatic lymph nodes (MLNs).

2. Materials and methods

This retrospective descriptive study was approved by the ethical committee of the Faculty of Medicine, Vajira Hospital, Navamindradhiraj University. We included all women with stage IA2, IB1 and IIA1 based on the 2018 FIGO staging system and underwent RHPL at Vajira Hospital from January 2005 to June 2020. We excluded the patients who received neo-adjuvant chemotherapy or had an incomplete medical record. Patients who loss of follow-up visit were also excluded.

Before 2018, the cancer stage was documented clinically by old FIGO staging criteria. A computerized tomography (CT) scan or magnetic resonance imaging (MRI) were unavailable for all patients. Type II or type III Piver hysterectomy with pelvic lymphadenectomy was performed by the experienced gynecologic oncologists. A para-aortic lymphadenectomy was considered when the pre-operative
imaging or intra-operative finding showed para-aortic lymphadenopathy.

The clinicopathological characteristics of all patients were age, surgical approach, cell type, cell differentiation, tumor size, stromal invasion, LVSI, surgical margin, number of RLN and MLN, FIGO 2008 and 2018 staging, adjuvant treatment and follow-up period.

The adjuvant treatments after surgery were prescribed for high-risk and intermediate-risk patients [11, 12]. The high-risk patients received concurrent chemoradiation (CCRT) based on the study of Peters WA et al. [11] and the intermediate-risk patients received radiation (RT) based on GOG-92 study [12]. The surveillance after treatment completion was every 3 months for the first 2 years, 6 months for 3–5 years, then annually.

All data were analyzed using STATA statistical software, version 15.1 (StataCorp, College Station, TX, USA). The descriptive statistics were used to analyze demographic data and were summarized as numbers with percentage, mean with standard deviation (SD) and median with range. Comparisons were made by a Chi-square or Fisher’s exact test for categorical variables and t-test for continuous variables. The independent sample t-test and Mann-Whitney U test were used to compare differences between two independent groups. Progression-free survival (PFS) and cancer-specific survival (CSS) of the patients were analyzed by the Kaplan-Meier method. The log-rank test was used to examine the statistical difference. Multivariate analysis of survival was performed by the Cox’s proportional hazard model. The statistical significance was considered when a p-value was less than 0.05.

3. Results

A total of 407 patients have met the inclusion criteria. Fifty-three patients were excluded because 33 had incomplete medical records, 13 were loss of follow-up and 7 received neo-adjuvant chemotherapy. Three-hundred-and-fifty-four patients were analyzed. The clinical and pathologic features display in Tables 1, 2. The median age at diagnosis of patients was 44 years (range: 22–88). Two most common histopathology were squamous cell carcinoma (63.3%) and adenocarcinoma (34.5%). The rare histopathology was neuroendocrine 6 cases (1.7%), undifferentiated 2 cases (0.6%). Ninety-one patients (25.7%) had received an adjuvant treatment after their operation because of the high-risk histopathological results including vaginal margin involvement in 7 cases (0.2%), parametrial involvement in 20 cases (6.5%), MLN in 36 cases (10.2%), deep stromal invasion in 47 cases (19.3%) and tumor size ≥2 cm in 211 cases (59.6%).

The median number of removed lymph node (RLN) was 23 (range: 17–29). The number of cases who had RLN 10 nodes or less, 11–20, 21–30, and 31 or more were 24 (6.8%), 114 (32.2%) 137 (38.7%) and 79 cases (22.3%), respectively. According to the recommendation of EORTC-GCG on pelvic lymphadenectomy specimens, 91.7% of our cases had ≥12 RLNs. The MLNs were found in 36 cases (10.2%). Increase of the number of RLNs does not significantly increase the detection of MLNs (p-value = 0.101).

Of 354 patients, the 5-year cancer-specific survival (CSS) was 95.48% and 5-year progression-free survival (PFS) was 97.89%. The 5-year CSS of the patients with RLNs <12 was significantly lower than the patients with RLNs ≥12 (73.6% and 97.0%, respectively) with p-value < 0.001 (Table 3 and Fig. 1). In subgroup analysis of node-negative patients, the 5-year CSS of the patients with RLNs <12 and ≥12 were 73.8% and 98.6%, respectively (p-value = 0.002). In term of 5-year PFS, there was no significant difference between the patients with RLNs <12 and ≥12 in entire cohort or subgroup analysis of node-negative patients. Based on lymph node status, the 5-year PFS and CSS of node-negative vs. node-positive patients were 99.3% vs. 76.2% and 97.5% vs. 74.0%, respectively (Table 3). There was a significant difference in survival between node-negative and node-positive groups.

![Fig. 1. Survival stratified by the groups of lymph nodes in early-stage cervical cancer. (A) Cancer-specific survival. (B) Progression-free survival.](image-url)

Of 7 recurrent cases (1.98%), 4 cases (57.2%) had local recurrence and 3 cases (42.8%) had distant recurrence. Five of 7 recurrent cases (71.4%) had MLNs after RHPL. The mortality rate was 4.2% (15 cases). Six of 15 death cases (40%) had positive lymph node and 9 of 15 had negative lymph node.
Table 1. Demographic and clinical data stratified by the number of pelvic nodes removed.

| Clinical characteristics | Total | <12 | >12 | p-value |
|-------------------------|-------|-----|-----|---------|
| Number of patients      | 354 (100.0) | 35 (8.3) | 319 (91.7) |       |
| Mean age (years) ± SD   | 44.6 ± 10.0 | 45.5 ± 10.5 | 44.5 ± 9.9 | 0.618 |
| Mean BMI (kg/m^2) ± SD  | 24.37 ± 3.67 | 23.7 ± 3.6 | 24.2 ± 4.3 | 0.538 |
| Surgical approach       |       |     |     |         |
| Laparotomy              | 342 (96.6) | 27 (93.1) | 309 (96.9) | 0.288 |
| Laparoscopy             | 12 (3.4) | 2 (6.9) | 10 (3.1) |         |
| Cell type               |       |     |     |         |
| Squamous cell carcinoma | 224 (63.3) | 13 (44.8) | 211 (64.9) | 0.159 |
| Adenocarcinoma          | 122 (34.5) | 15 (51.7) | 107 (32.9) |         |
| Undifferentiated        | 2 (0.6) | 0 (0) | 2 (0.6) |         |
| Neuroendocrine          | 6 (1.7) | 1 (3.4) | 5 (1.5) |         |
| Adjuvant treatment      |       |     |     |         |
| No                      | 263 (74.3) | 19 (65.5) | 244 (75.1) | 0.259 |
| Yes                     | 91 (25.7) | 10 (34.5) | 81 (24.9) |         |
| - CCRT                  | 61 (17.2) | 7 (24.1) | 54 (16.6) |         |
| - RT                    | 22 (6.2) | 2 (6.9) | 20 (6.2) |         |
| - CMT                   | 8 (2.3) | 1 (3.4) | 7 (2.2) |         |

SD, standard deviation; BMI, body mass index; RLNs, removed lymph nodes; CCRT, concurrent chemoradiation; RT, radiation; CMT, chemotherapy.

A significant prognostic factor for PFS was MLN which a hazard ratio (HR) was 11.05 on univariate analysis (95% CI: 2.43–50.20, p-value = 0.002) and 8.60 on multivariate analysis (95% CI: 1.81–40.79, p-value = 0.007) (Table 4 and Fig. 2). The other factors including age, surgical approach, cell type, histologic grade, tumor size, stromal invasion, LVSI, vaginal margin, parametrial involvement, total number of RLNs, FIGO stage and adjuvant treatment, were not significant prognostic factors for PFS. In term of CSS, adenocarcinoma, moderate and high grade, RLNs <12, positive lymph node and adjuvant treatment were significant prognostic factors on univariate analysis. The multivariate analysis showed RLNs <12, positive lymph node and adjuvant treatment to be independent prognostic factors for CSS with HR 5.21 (95% CI: 1.49–18.16, p-value = 0.009), 3.86 (95% CI: 1.01–14.84, p-value = 0.049) and 7.42 (95% CI: 1.66–33.15, p-value = 0.009), respectively.

4. Discussion

The EORTC-GCG purposed the quality assurance for RHPL for cervical cancer in 2008 in order to audit and assure the quality of surgical care [10]. The recommended minimum number of removed pelvic lymph node is 12. In our study, the median number of RLNs was 23 and 91.7% of all cases had ≥12 RLNs. Supasert P et al. [13] studied 843 cervical cancer patients in Chiangmai, Thailand and exclude 17 patients with RLN less than 11. They reported that the mean number of RLNs was 26. Other literatures revealed the median number of RLN, ranging from 17–34 lymph nodes [9, 14–16].

The benefit of more extensive lymphadenectomy in early-stage cervical cancer had been proved in our study. RLNs ≥12 is associated with 5-yr CSS of early-stage cervical cancer patient with negative LN but it is not associated with 5-
Table 2. Pathological characteristics stratified by the number of pelvic nodes removed.

| Pathological characteristics | Total Number of RLNs | p-value |
|-----------------------------|----------------------|---------|
|                             | <12                  | >12     |
| Histologic grade            |                      |         |
| Low                         | 140 (45.3)           | 9 (31.0)| 131 (40.3) | 0.671 |
| Moderate                    | 142 (46.0)           | 14 (48.3)| 128 (39.4) |
| High                        | 27 (8.7)             | 3 (4.0) | 24 (7.4)   |
| Tumor size (cm)             |                      |         |
| <2                          | 143 (40.4)           | 14 (48.3)| 129 (39.7) | 0.367 |
| ≥2                          | 211 (59.6)           | 15 (52.2)| 196 (60.3) |
| Stromal invasion            |                      |         |
| Superficial                 | 131 (53.7)           | 11 (47.8)| 120 (54.3) | 0.680 |
| Middle                      | 66 (27.0)            | 8 (34.8) | 58 (26.2)  |
| Deep                        | 47 (19.3)            | 4 (17.4)| 43 (19.5)  |
| LVSI                        |                      |         |
| Not present                 | 250 (80.9)           | 23 (94.6)| 274 (97.9) | 0.818 |
| Present                     | 59 (19.1)            | 1 (5.4) | 6 (2.1)    |
| Vaginal margin involvement  |                      |         |
| Not present                 | 301 (97.7)           | 27 (88.4)| 179 (82.9) | 0.629 |
| Present                     | 7 (2.3)              | 2 (1.6) | 5 (2.1)    |
| Parametrial involvement     |                      |         |
| Not present                 | 289 (93.5)           | 27 (93.1)| 262 (93.6) | 0.922 |
| Present                     | 20 (6.5)             | 2 (6.9) | 18 (6.4)   |
| Lymph node metastasis       |                      |         |
| Negative                    | 318 (89.8)           | 24 (82.8)| 294 (90.5) | 0.189 |
| Positive                    | 36 (10.2)            | 5 (17.2) | 31 (9.5)   |
| Lymph node metastasis       |                      |         |
| Negative                    | 318 (89.8)           | 24 (82.8)| 294 (90.5) | 0.237 |
| Positive ≤5                 | 32 (9.0)             | 5 (17.2) | 27 (8.3)   |
| Positive >5                 | 4 (1.1)              | 0 (0.0) | 4 (1.2)    |

RLNs, removed lymph nodes; LVSI, lymphovascular space invasion.

Table 3. Five-years for progression-free survival (PFS) and cancer-specific survival (CSS).

| Variables | 5-year PFS (%) | p-value | 5-year CSS (%) | p-value |
|-----------|----------------|---------|----------------|---------|
| Age (years) |                |         |                |         |
| <60       | 97.46          | 0.851   | 93.44          | 0.114   |
| ≥60       | 98.35          | 98.02   |                |         |
| Surgical approach |          |         |                |         |
| Laparotomy | 97.76          | 0.814   | 95.71          | 0.504   |
| Laparoscopy | 100.00         | 85.71   |                |         |
| Cell type   |                |         |                |         |
| Squamous cell carcinoma | 99.01          | 0.965   | 97.06          | 0.089   |
| Adenocarcinoma | 97.23          |         | 92.34          |         |
| Undifferentiated | 100.00         |         | 100.00         |         |
| Neuroendocrine | 100.00         |         | 100.00         |         |
| Histologic grade |            |         |                |         |
| Low        | 100.00         | 0.088   | 98.94          | 0.038   |
| Moderate   | 94.56          |         | 91.92          |         |
| High       | 100.00         |         | 90.63          |         |
| Tumor size (cm) |          |         |                |         |
| <2         | 97.37          | 0.928   | 96.60          | 0.709   |
| ≥2         | 98.29          |         | 94.70          |         |
| Stromal invasion |        |         |                |         |
| Superficial | 99.21          | 0.129   | 97.44          | 0.110   |
| Middle     | 95.35          |         | 87.29          |         |
| Deep       | 93.66          |         | 94.66          |         |
| LVSI       |                |         |                |         |
| Not present | 97.87          | 0.321   | 95.54          | 0.154   |
| Present    | 94.74          |         | 88.80          |         |
| Vaginal margin |            |         |                |         |
| Not present | 97.27          | 0.302   | 94.25          | 0.537   |
| Present    | 100.00         |         | 100.00         |         |
| Parametrial involvement |        |         |                |         |
| Not present | 98.17          | 0.211   | 94.05          | 0.434   |
| Present    | 87.50          |         | 100.00         |         |
| Total number of RLNs |            |         |                |         |
| <12        | 96.00          | 0.387   | 73.60          | <0.001  |
| ≥12        | 98.10          |         | 97.00          |         |
| Lymph node metastasis |          |         |                |         |
| Negative   | 99.32          | <0.001  | 97.54          | <0.001  |
| Positive   | 76.23          |         | 74.02          |         |
| Lymph node metastasis |          |         |                |         |
| Negative   | 99.32          | <0.001  | 97.54          | <0.001  |
| Positive ≤5 | 79.55          |         | 79.2           |         |
| Positive >5 | NR             |         | NR             |         |

RLNs, removed lymph nodes; LVSI, lymphovascular space invasion; PFS, progression-free survival; CSS, cancer-specific survival.

yr PFS. Wang R et al. [15] found the therapeutic benefit of lymphadenectomy in stage IB1 cervical cancer patients. The PFS and CSS of the patients with <10 RLNs were significantly lower than those with >10 RLNs (p-value = 0.026 and 0.012, respectively). A large retrospective study using SEER database, enrolled 5522 women with cervical cancer stage IA2–IIA from 1988–2005 [8]. In the entire cohort and node-negative patients, the hazard ratio (HR) of the patients with >30 RLNs, comparing with the patients with ≤10 RLNs, was 0.71 and 0.64, respectively. On the contrary, some previous report did not find the relation between RLN number and DFS or CSS in the patient with negative LN [9, 13, 14, 16]. In subgroup analysis of node-positive patient, there is no correlation between the number of RLN and DFS or CSS [8, 13, 15, 16]. One study demonstrated the benefit of lymphadenectomy in 136 patients with MLN [14]. The number of RLN in this group was associated with DFS with p-value of 0.014 but there was no correlation with CSS. The rate of MLN in our cohort was 10.2% (36 cases) which was lower than previous reports, ranging from 14.1–19.4% [8, 13, 15–17] so the authors cannot perform subgroup-analysis on survival.

Lymph node status is one of the important prognostic factors in early-stage cervical cancer patients underwent RHPL [4, 7]. The DFS and OS were significantly different between the patients with and without MLN [18, 19]. The number of MLN is associated with survival. The patients with >2 MLNs had a significantly lower rate of DFS and OS, compared to those with 1–2 MLNs [4, 6]. Our result showed a similar trend. The 5-yr PFS and CSS of node-positive patients were significantly lower than node-negative patients.
Table 4. Univariate and multivariate analysis for progression-free survival and cancer-specific survival.

| Factors                  | Progression-free survival | Cancer-specific survival |
|--------------------------|---------------------------|-------------------------|
|                          | Univariate analysis       | Multivariate analysis   | Univariate analysis | Multivariate analysis |
|                          | HR            | 95% CI    | p-value | HR   | 95% CI    | p-value | HR   | 95% CI    | p-value |
| Age (yr)                 |                |           |         | HR   | 95% CI    | p-value | HR   | 95% CI    | p-value |
| <60                      | 1.00          | Reference |         | 1.00 | Reference |         | 1.00 | Reference |         |
| ≥60                      | 0.87          | (0.19–3.88) | 0.851   | 0.41 | (0.13–1.27) | 0.123 |
| Surgical approach        |                |           |         | HR   | 95% CI    | p-value | HR   | 95% CI    | p-value |
| Laparotomy               | 1.00          | Reference |         | 1.00 | Reference |         | 1.00 | Reference |         |
| Laparoscopy              | -             | NA        |         | 2.81 | (0.36–21.97) | 0.325 |
| Cell type                |                |           |         | HR   | 95% CI    | p-value | HR   | 95% CI    | p-value |
| Squamous cell carcinoma  | 1.00          | Reference |         | 1.00 | Reference |         | 1.00 | Reference |         |
| Adenocarcinoma           | 0.77          | (0.15–3.99) | 0.758   | 3.02 | (1.03–8.82) | 0.043 | 1.70 | (0.47–6.13) | 0.415 |
| Histologic grade         |                |           |         | HR   | 95% CI    | p-value | HR   | 95% CI    | p-value |
| Low                      | 1.00          | Reference |         | 1.00 | Reference |         | 1.00 | Reference |         |
| Moderate                 | 6.31          | (0.76–52.46) | 0.088 | 4.02 | (1.01–16.03) | 0.049 | 2.42 | (0.50–11.76) | 0.274 |
| High                     | -             | NA        |         | 6.39 | (1.26–32.55) | 0.026 | 2.91 | (0.36–23.25) | 0.313 |
| Tumor size (cm)          |                |           |         | HR   | 95% CI    | p-value | HR   | 95% CI    | p-value |
| <2                       | 1.00          | Reference |         | 1.00 | Reference |         | 1.00 | Reference |         |
| ≥2                       | 0.93          | (0.20–4.17) | 0.928   | 1.23 | (0.42–3.63) | 0.709 |
| Stromal invasion         |                |           |         | HR   | 95% CI    | p-value | HR   | 95% CI    | p-value |
| Superficial              | 1.00          | Reference |         | 1.00 | Reference |         | 1.00 | Reference |         |
| Middle                   | 3.96          | (0.36–43.78) | 0.262 | 2.48 | (0.22–28.61) | 0.466 | 5.10 | (0.99–26.28) | 0.052 |
| Deep                     | 6.87          | (0.71–66.66) | 0.096 | 5.26 | (0.54–51.44) | 0.153 | 2.36 | (0.33–16.81) | 0.392 |
| LVSI                     |                |           |         | HR   | 95% CI    | p-value | HR   | 95% CI    | p-value |
| Not present              | 1.00          | Reference |         | 1.00 | Reference |         | 1.00 | Reference |         |
| Present                  | 0.72          | (0.09–3.98) | 0.760   | 2.48 | (0.72–8.50) | 0.148 |
| Vaginal margin           |                |           |         | HR   | 95% CI    | p-value | HR   | 95% CI    | p-value |
| Not present              | 1.00          | Reference |         | 1.00 | Reference |         | 1.00 | Reference |         |
| Present                  | -             | NA        |         | 0.00 | (NR)      | 1.000 |
| Parametrial involvement  |                |           |         | HR   | 95% CI    | p-value | HR   | 95% CI    | p-value |
| Not present              | 1.00          | Reference |         | 1.00 | Reference |         | 1.00 | Reference |         |
| Present                  | 2.45          | (0.29–20.41) | 0.407   | 0.00 | (NR)      | 1.000 |
Table 4. Continued.

| Factors                        | Progression-free survival | Cancer-specific survival |
|-------------------------------|---------------------------|-------------------------|
|                               | Univariate analysis      | Multivariate analysis   | Univariate analysis | Multivariate analysis |
|                               | HR     | 95% CI   | p-value | HR adj  | 95% CI   | p-value | HR     | 95% CI   | p-value | HR adj  | 95% CI   | p-value |
| Total number of RLNs          |                    |                      |         |         |                  |         |         |                  |         |                  |         |
| <12                           | 2.43   | (0.29–20.88) | 0.403 | 2.85   | (0.31–25.76) | 0.930 | 6.90   | (2.03–23.37) | 0.002 | 5.21   | (1.49–18.16) | 0.009 |
| ≥12                           | 1.00   | Reference | 1.00   | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference |
| Lymph node metastasis         |                    |                      |         |         |                  |         |         |                  |         |                  |         |
| Negative                      | 1.00   | Reference | 1.00   | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference |
| Positive                      | 11.05  | (2.43–50.20) | 0.002 | 8.60   | (1.81–40.79) | 0.007 | 15.09  | (4.56–49.91) | <0.001 | 3.86   | (1.01–14.84) | 0.049 |
| Positive ≤5                   | 7.97   | (1.44–44.08) | 0.017 | 10.94  | (2.91–41.06) | 0.001 |
| Positive >5                   | 117.52 | (9.62–1436.04) | <0.001 | 100.42 | (17.18–587.07) | <0.001 |
| FIGO stage                    |                    |                      |         |         |                  |         |         |                  |         |                  |         |
| IA2–IB3                       | 1.00   | Reference | 1.00   | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference |
| IIA1–IIB                      | 1.62   | (0.19–13.50) | 0.655 | 2.01   | (0.44–9.26) | 0.371 |
| Adjuvant treatment            |                    |                      |         |         |                  |         |         |                  |         |                  |         |
| No                            | 1.00   | Reference | 1.00   | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference |
| Yes                           | 2.39   | (0.53–10.69) | 0.256 | 11.10  | (3.45–35.72) | <0.001 | 7.42   | (1.66–33.15) | 0.009 |

RLNs, removed lymph nodes; LVSI, lymphovascular space invasion.
Additionally, the authors found that the recurrence rate in node-positive patients was greater than that of the node-negative patients.

The surgical complications associated with lymphadenectomy are lymphedema, lymphocyst formation, blood vessel or nerve injury etc. Lower lymphadenoma is one of the most common complication effecting the quality of life of many patients. A systematic review including 23 articles, revealed the factors associated with lymphedema after treatment of cervical cancer [20]. The extension of lymphadenectomy and number of RLNs increase the risk of lymphedema [20]. Sentinel lymph node (SNL) mapping might be a promising option to minimize the risk of lower limb lymphedema. A systematic review and meta-analysis showed that the pooled detection rate and sensitivity of SLN mapping was 89.2% and 90%, respectively [21]. A retrospective study at MD Anderson Cancer Center, US included 188 patients underwent SLN mapping [22]. A false negative rate in this study was 3.6%. Lennox et al. [23] compared a survival outcome between 1078 cervical cancer patients in pelvic lymphadenectomy group and 110 patients in SLN mapping group. There was no difference in 2-year and 5-year recurrence-free survival. SLN mapping with ultra-staging protocol might be helpful to detect an MLN including micro-metastasis and isolated tumor cells. These patients would be received a proper adjuvant treatment by the accurate stage.

Lymphadenectomy in our institute is up to the standard of EORTC-GCC. The authors reported the benefit of lymphadenectomy on survival of early-stage cervical cancer patients. Although some histopathologic results including lymph node status are incomplete because of the retrospective data and counting method of lymph node may be different among pathologists, these were reviewed by a pathologist to obtain the complete results. This study was conducted in one center so the number of patients is inadequate to perform subgroup analysis, especially node-positive group. In addition, the pre-operative imaging study was unavailable for all patients. The further study should be prospectively and collaborated with multicenter.

5. Conclusions

In conclusion, an extensive lymphadenectomy had a survival benefit in early-stage cervical cancer patients. The patients with RLNs ≥12 had better 5-year CSS, MLNs and RLNs <12 are significant prognostic factors for PFS and CSS. Precise detection of positive lymph node is important to prescribe the appropriate adjuvant treatment and determine the exact prognosis.

Author contributions

PI collected the data, managed the database, performed the statistical analysis and wrote the manuscript. WC designed the study, managed the database, performed the statistical analysis and edited the manuscript. NB performed the pathological review and edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Participant of patients in this study was obtained through an opt-out methodology. The institutional review board of Faculty of Medicine Vajira Hospital, Navamindradhiraj University approved the study, code 042/63.

Acknowledgment

The authors thank to all staffs in gynecologic oncology unit, department of obstetrics and gynecology, faculty of medicine, Navamindradhiraj University for their opinions and suggestions during preparation of the manuscript.

Funding

This research was funded by Navamindradhiraj University Research Fund, grant number 17/2564.

Conflict of interest

The authors declare no conflict of interest.

References

[1] International Agency for Research on Cancer. Population fact sheets. 2018. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdf (Accessed: 24 August 2020).

[2] Insamran W. 2018 Cancer incidence in Thailand: cervical cancer. Cancer in Thailand. 2018; IV: 77.

[3] Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. International Journal of Gynecology & Obstetrics. 2018; 143: 22–36.

[4] Liu Y, Ni L, Wang S, Lv Q, Chen W, Ying S. Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy: a retrospective study. World Journal of Surgical Oncology. 2018; 16: 18.

[5] Yan D, Tang Q, Chen J, Tu Y, Lv X. Prognostic value of the 2018 FIGO staging system for cervical cancer patients with surgical risk factors. Cancer Management and Research. 2019; 11: 5473–5480.

[6] Li D, Xu X, Yan D, Yuan S, Ni J, Lou H. Prognostic factors affecting survival and recurrence in patients with early cervical squamous cell cancer following radical hysterectomy. Journal of International Medical Research. 2020; 48: 030006051988974.

[7] Thanabhinunt P, Nakariyakul B, Wasinghon P. Prognostic factors and survival rates in early-stage cervical p Treated with Radical Hysterectomy and Pelvic Lymphadenectomy. Thai Journal of Obstetrics and Gynaecology. 2018; 26: 270–281.

[8] Shah M, Lewin SN, Deutsch I, Burke WM, Sun X, Herzog TJ, et al. Therapeutic role of lymphadenectomy for cervical cancer. Cancer. 2011; 117: 310–317.

[9] Mao S, Dong J, Li S, Wang Y, Wu P. Prognostic significance of number of nodes removed in patients with node-negative early cervical cancer, Journal of Obstetrics and Gynaecology Research. 2016; 42: 1317–1325.

[10] Verleye L, Vergote I, Reed N, Ottevanger PB. Quality assurance for radical hysterectomy for cervical cancer: the view of the European Organization for Research and Treatment of Cancer—Gynecological Cancer Group (EORTC-GCG) Annals of Oncology. 2009; 20: 1631–1638.

[11] Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Journal of Clinical Oncology. 2000; 18: 1606–1613.

[12] Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the
cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecologic Oncology. 1999; 73: 177–183.

[13] Suprasert P, Charoenkwan K, Khunamornpong S. Pelvic node removal and disease-free survival in cervical cancer patients treated with radical hysterectomy and pelvic lymphadenectomy. International Journal of Gynaecology and Obstetrics. 2012; 116: 43–46.

[14] Pieterse QD, Kenter GG, Gaarenstroom KN, Peters AAW, Willems SM, Fleuren GJ, et al. The number of pelvic lymph nodes in the quality control and prognosis of radical hysterectomy for the treatment of cervical cancer. European Journal of Surgical Oncology. 2007; 33: 216–221.

[15] Wang R, Tao X, Wu X, Jiang H, Xia H. Number of Removed Pelvic Lymph Nodes as a Prognostic Marker in FIGO Stage IB1 Cervical Cancer with Negative Lymph Nodes. Journal of Minimally Invasive Gynecology. 2020; 27: 946–952.

[16] Ditto A, Martinelli F, Lo Vullo S, Reato C, Solima E, Carcangiu M, et al. The role of lymphadenectomy in cervical cancer patients: the significance of the number and the status of lymph nodes removed in 526 cases treated in a single institution. Annals of Surgical Oncology. 2013; 20: 3948–3954.

[17] Bogani G, Vinti D, Murgia F, Chiappa V, Leone Roberti Maggiore U, Martinelli F, et al. Burden of lymphatic disease predicts efficacy of adjuvant radiation and chemotherapy in FIGO 2018 stage II-ICp cervical cancer. International Journal of Gynecologic Cancer. 2019; 29: 1355–1360.

[18] Zeng J, Qu P, Hu Y, Sun P, Qi J, Zhao G, et al. Clinicopathological risk factors in the light of the revised 2018 International Federation of Gynecology and Obstetrics staging system for early cervical cancer with staging IB. Medicine. 2020; 99: e19714.

[19] Nanthamongkolkul K, Hanprasertpong J. Predictive Factors of Pelvic Lymph Node Metastasis in Early-Stage Cervical Cancer. Oncology Research and Treatment. 2018; 41: 194–198.

[20] Bona AF, Ferreira KR, Carvalho RBDM, Thuler LCS, Bergmann A. Incidence, prevalence, and factors associated with lymphedema after treatment for cervical cancer: a systematic review. International Journal of Gynecologic Cancer. 2020; 30: 1697–1704.

[21] Kadkhodayan S, Hasanzadeh M, Treglia G, Azad A, Yousefi Z, Zarifmahmoudi L, et al. Sentinel node biopsy for lymph nodal staging of uterine cervix cancer: a systematic review and meta-analysis of the pertinent literature. European Journal of Surgical Oncology. 2015; 41: 1–20.

[22] Salvo G, Ramirez PT, Levenback CF, Munsell MF, Euscher ED, Soliman PT, et al. Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer. Gynecologic Oncology. 2017; 145: 96–101.

[23] Lennox GK, Covens A. Can sentinel lymph node biopsy replace pelvic lymphadenectomy for early cervical cancer? Gynecologic Oncology. 2017; 144: 16–20.